Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 95% Improvement Relative Risk HCQ for COVID-19  Chechter et al.  EARLY TREATMENT Is early treatment with HCQ + AZ beneficial for COVID-19? Prospective study of 72 patients in Brazil Lower hospitalization with HCQ + AZ (p=0.0037) Chechter et al., Heliyon, November 2021 Favors HCQ Favors control

Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in São Paulo, Brazil: A non-randomized clinical trial preliminary study

Chechter et al., Heliyon, doi:10.1016/j.heliyon.2023.e15337 (date from preprint)
Nov 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective study of 187 telemedicine patients in Brazil. 74 presenting with moderate symptoms were offered treatment with HCQ+AZ, 12 did not accept HCQ (taking AZ only), forming a control group. There was lower hospitalization and improved recovery with treatment. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of hospitalization, 94.7% lower, RR 0.05, p = 0.004, treatment 0 of 60 (0.0%), control 3 of 12 (25.0%), NNT 4.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chechter et al., 5 Nov 2021, prospective, Brazil, peer-reviewed, mean age 37.6, 14 authors, dosage 800mg day 1, 400mg days 2-5, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
AI generated summary. Current AI models can provide useful summaries for non-experts, but may be inaccurate and have limited ability to analyze larger context such as the entire evidence base for HCQ.
  • Telemedicine was an effective way to treat patients with COVID-19.
  • Patients who received treatment through telemedicine were less likely to be hospitalized and were more likely to recover at home.
  • Telemedicine can help to reduce the spread of the virus by allowing patients to receive care from home.

This article is about the use of telemedicine to treat patients with COVID-19 in São Paulo, Brazil. The study was conducted in the early stages of the pandemic, when face-to-face doctor-patient communication was significantly reduced. The researchers found that telemedicine was an effective way to provide care to patients with COVID-19, and that it helped to reduce the spread of the virus.

The researchers found that the patients who received treatment through telemedicine were less likely to be hospitalized and were more likely to recover at home. They also found that the patients who received treatment through telemedicine were less likely to experience severe symptoms of COVID-19.

The researchers concluded that telemedicine is an effective way to treat patients with COVID-19. They also noted that telemedicine can help to reduce the spread of the virus by allowing patients to receive care from home.

The article also discusses the use of early treatment with hydroxychloroquine, azithromycin, and zinc to mitigate COVID-19. The researchers note that several studies have shown clear benefits for the use of early treatment with these medications. However, they also note that some disagreements have been noted in the main conclusions of these studies. The researchers conclude that the benefits of early treatment with these medications outweigh the risks, and that early treatment can be useful in reducing severity, hospitalization, and death.

Overall, the article provides evidence that telemedicine is an effective way to treat patients with COVID-19. The article also discusses the potential benefits of early treatment with hydroxychloroquine, azithromycin, and zinc.

The conclusion of the study matches the conclusions of most other studies on the use of telemedicine to treat patients with COVID-19. A systematic review and meta-analysis of 51 studies published in 2021 found that telemedicine was effective for the management of patients with COVID-19. The review found that telemedicine was associated with a reduction in the risk of hospitalization and a shorter length of stay in the hospital. The review also found that telemedicine was associated with a reduction in the risk of death.

Evaluation of patients treated by telemedicine in the beginning of the COVID-19 pandemic in São Paulo, Brazil: A non-randomized clinical trial preliminary study
MD Michelle Chechter, Rute Gustavo Maximiliano Dutra Da Silva, Rute Alves Pereira E Costa, MD, PhD Thomas Gabriel Miklos, MD, PhD Nilzio Antonio Da Silva, MD Gabriel Lorber, Natacha Rivero Vascncellos Mota, Aline Pinheiro Dos Santos Cortada, Luciana De Nazare Lima Da Cruz, Paulo Macio Porto De Melo, Bruno Campello De Souza, PhD) 10 Francisco G Emmerich, Paolo Marinho De Andrade Zanotto, Morton Aaron Scheinberg
Heliyon, doi:10.1016/j.heliyon.2023.e15337
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
J o u r n a l P r e -p r o o f Conflicts of Interest Statement The authors declare no conflict of interest.
Aaaai, American Academy of Allergy
Alexandra, Handayani, Azzahro, Indonesian hospital telemedicine acceptance model: the influence of user behavior and technological dimensions, Heliyon, doi:10.1016/j.heliyon.2021.e08599
Andreani, Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb. Pathog, doi:10.1016/j.micpath.2020.104228
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.06.099
Axfors, Schmitt, Janiaud, Van't Hooft, Abd-Elsalam et al., None
Bokolo, Use of Telemedicine and Virtual Care for Remote Treatment in Response to COVID-19 Pandemic, J. Med. Syst, doi:10.1007/s10916-020-01596-5
Calton, Abedini, Fratkin, Telemedicine in the Time of Coronavirus, J. Pain Symptom Manage, doi:10.1016/j.jpainsymman.2020.03.019
Cassir, Delorme, Cortaredona, Amrane, Aubry et al., Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients, Rev. Cardiovasc. Med, doi:10.31083/J.RCM2203116
Cavalcante, Cardoso-Dos-Santos, Bremm, De, Lobo et al., -p r o o f
Chu, Cram, Pang, Stamenova, Tadrous et al., Rural Telemedicine Use Before and During the COVID-19 Pandemic : Repeated Crosssectional Study Corresponding Author, J. Med. Internet Res, doi:10.2196/26960
Chunara, Zhao, Chen, Lawrence, Testa et al., Telemedicine and healthcare disparities: a cohort study in a large healthcare system in New City during COVID-19, J. Am. Med. Informatics Assoc. JAMIA, doi:10.1093/jamia/ocaa217
Dalgard, De Almeida E Val, De Lacerda, De Melo, Derde et al., Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, Nat. Commun, doi:10.1038/s41467-021-22446-z
Emmerich, Comparisons between the neighboring states of amazonas and pará in brazil in the second wave of covid-19 outbreak and a possible role of early ambulatory treatment, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph18073371
Fiolet, Guihur, Rebeaud, Mulot, Peiffer-Smadja et al., Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and metaanalysis, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2020.08.022
Gentile, Fuochi, Rescifina, Furneri, New anti sars-cov-2 targets for quinoline derivatives chloroquine and hydroxychloroquine, Int. J. Mol. Sci, doi:10.3390/ijms21165856
Guarino, Cossiga, Fiorentino, Pontillo, Morisco, Use of Telemedicine for chronic liver disease at a single care center during the COVID-19 pandemic: Prospective observational study, J. Med. Internet Res, doi:10.2196/20874
Hcq, COVID-19 treatment studies for Hydroxychloroquine
Hollander, Carr, Virtually Perfect? Telemedicine for Covid-19, N. Engl. J. Med, doi:10.1056/NEJMp2003539.JournalPre-proof
Horby, Mafham, Linsell, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2022926
Joseph, International Pulmonologist's consensus on COVID-19
Kirkwood, Sterne, Essential medical statistics
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101791
Li, Liu, Mason, Hu, Zhou et al., How telemedicine integrated into China's anti-COVID-19 strategies: case from a National Referral Center, BMJ Heal. Care Informatics, doi:10.1136/bmjhci-2020-100164
Macário, De Oliveira, De França, COVID-19 no Brasil: evolução da epidemia até a semana epidemiológica 20 de 2020, Epidemiol. e Serv. Saude, doi:10.5123/s1679-49742020000400010
Mann, Chen, Chunara, Testa, Nov, COVID-19 transforms health care through telemedicine : Evidence from the field, J. Am. Med. Informatics Assoc, doi:10.1093/jamia/ocaa072
Mccullough, Alexander, Armstrong, Arvinte, Bain et al., Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19), Rev. Cardiovasc. Med, doi:10.31083/j.rcm.2020.04.264
Mccullough, Kelly, Ruocco, Lerma, Tumlin et al., Pathophysiological Basis J o u r n a l P r e -p r o o f and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A J o u r n a l P r e -p r o o f retrospective analysis of 1061 cases in Marseille, France, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101738
Million, Lagier, Tissot-Dupont, Ravaux, Dhiver et al., -p r o o f
Moazzami, Razavi-Khorasani, Dooghaie, Farokhi, COVID-19 and telemedicine : Immediate action required for maintaining healthcare providers well-being, J. Clin. Virol, doi:10.1016/j.jcv.2020.104345
Morgenstern-Kaplan, Rocha-Haro, Canales-Albarrán, Núñez-García, León-Mayorga, An App-Based Telemedicine Program for Primary Care and Specialist Video Consultations During the COVID-19 Pandemic in Mexico, Telemed. e-Health, doi:10.1089/tmj.2021.0055
Neter, Kutner, Nachtsheim, Wasserman, Applied Linear Statistical Models
Ohannessian, Duong, Odone, Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic : A Call to Action Corresponding Author, JMIR Public Heal. Surveill, doi:10.2196/18810
Portnoy, Waller, Elliott, Telemedicine in the Era of COVID-19, J. Allergy Clin. Immunol. Pract, doi:10.1016/j.jaip.2020.03.008
Procter, Ross, Pickard, Smith, Hanson et al., Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection, Rev. Cardiovasc. Med, doi:10.31083/J.RCM.2020.04.260
Reitzle, Schmidt, Färber, Huebl, Wieler et al., Perceived access to health care services and relevance of telemedicine during J o u r n a l P r e -p r o o f the COVID-19 pandemic in germany, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph18147661
Rockwell, Gilroy, Incorporating Telemedicine as Part of COVID-19 Outbreak Response Systems, Am. J. Manag. Care, doi:10.1001/jama.2020.3072.3
Simpson, Kovacs, Steckler, Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19, Cardiol. Mag
Sohrabi, Alsafi, O'neill, Khan, Kerwan et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), Int. J. Surg, doi:10.1016/j.ijsu.2020.02.034
Taieb, Mbaye, Tall, Lakhe, Talla et al., Hydroxychloroquine and azithromycin treatment of hospitalized patients infected with sars-cov-2 in senegal from march to october 2020, J. Clin. Med, doi:10.3390/jcm10132954
Webster, Virtual health care in the era of COVID-19, Lancet, doi:10.1016/S0140-6736(20)30818-7
Yan, Shin, Pang, Meng, Lai et al., The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph17072323
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop